Gennex Laboratories Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Arihant Baid

İcra Kurulu Başkanı

₹3.0m

Toplam tazminat

CEO maaş yüzdesi	99.0%
CEO görev süresi	12.5yrs
CEO sahipliği	0.00007%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Arihant Baid'un ücretlendirmesi Gennex Laboratories'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	₹150m
Mar 31 2024	₹3m	₹3m	₹132m
Dec 31 2023	n/a	n/a	₹107m
Sep 30 2023	n/a	n/a	₹90m
Jun 30 2023	n/a	n/a	₹70m
Mar 31 2023	₹3m	₹3m	₹49m
Dec 31 2022	n/a	n/a	₹40m
Sep 30 2022	n/a	n/a	₹37m
Jun 30 2022	n/a	n/a	₹37m
Mar 31 2022	₹3m	₹3m	₹39m
Dec 31 2021	n/a	n/a	₹44m
Sep 30 2021	n/a	n/a	₹49m
Jun 30 2021	n/a	n/a	₹46m
Mar 31 2021	₹3m	₹3m	₹40m
Dec 31 2020	n/a	n/a	₹28m
Sep 30 2020	n/a	n/a	₹17m
Jun 30 2020	n/a	n/a	₹14m
Mar 31 2020	₹3m	₹3m	₹19m
Dec 31 2019	n/a	n/a	₹20m
Sep 30 2019	n/a	n/a	₹27m
Jun 30 2019	n/a	n/a	₹25m
Mar 31 2019	₹3m	₹3m	₹22m
Dec 31 2018	n/a	n/a	₹16m
Sep 30 2018	n/a	n/a	₹10m
Jun 30 2018	n/a	n/a	₹10m
Mar 31 2018	₹3m	₹2m	₹8m

Tazminat ve Piyasa: Arihant 'ın toplam tazminatı ($USD 36.02K ) Indian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 42.81K ).

Tazminat ve Kazançlar: Arihant 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Arihant Baid (38 yo)

12.5yrs

Görev süresi

₹3,028,800

Tazminat

Mr. Arihant Baid has been Managing Director of Gennex Laboratories Limited since March 2011 and serves as its Executive Director since May 18, 2012. Mr. Baid serves as Chairman of Gennex Laboratories Limit...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Arihant Baid	Chairman & MD	12.5yrs	₹3.03m	0.000070% ₹ 3.3k
Amudala Sreeramulu Rao	Non-Executive & Independent Director	3.9yrs	Veri yok	Veri yok
Avasarala Ranga Pantulu	Non-Executive & Non-Independent Director	3.9yrs	Veri yok	Veri yok
Shilpa Bung	Independent Non-Executive Woman Director	less than a year	Veri yok	Veri yok
S. Ch. Rao	Additional Non- Executive Non Independent Director	less than a year	Veri yok	Veri yok
Mohammed Rahman	Additional Non- Executive-Non Independent Director	less than a year	Veri yok	Veri yok
Dilip Singhvi	Independent Non-Executive Director	less than a year	Veri yok	0.029% ₹ 1.3m

0.8yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 531739 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Gennex Laboratories Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Gennex Laboratories Limited Announces Board Changes

Gennex Laboratories Limited, Annual General Meeting, Sep 30, 2024

Gennex Laboratories Limited Approves Appointment of Mohammed Khaleequr Rahman as Additional Director (Non- Executive-Non Independent)

Laxmipat Baid Tenders Resignation from the Post of Chief Financial Officer (Key Managerial Personnel) of Gennex Laboratories Limited

Gennex Laboratories Limited Announces Resignation of Tiruvarur Muralidharan Gopalakrishnan as Whole Time Director

Insufficient new directors

Recent updates

Gennex Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024

Gennex Laboratories Limited Announces Board Changes

Investor sentiment deteriorates as stock falls 15%

New minor risk - Share price stability

Gennex Laboratories Limited, Annual General Meeting, Sep 30, 2024

Investor sentiment improves as stock rises 19%

Gennex Laboratories Limited Approves Appointment of Mohammed Khaleequr Rahman as Additional Director (Non- Executive-Non Independent)

Investor sentiment improves as stock rises 18%

Laxmipat Baid Tenders Resignation from the Post of Chief Financial Officer (Key Managerial Personnel) of Gennex Laboratories Limited

Gennex Laboratories Limited to Report Q1, 2025 Results on Aug 14, 2024

Full year 2024 earnings released: EPS: ₹0.67 (vs ₹0.34 in FY 2023)

Gennex Laboratories Limited to Report Q4, 2024 Results on May 30, 2024

Investor sentiment improves as stock rises 24%

Investor sentiment improves as stock rises 20%

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 20%

Third quarter 2024 earnings released: EPS: ₹0.16 (vs ₹0.067 in 3Q 2023)

Gennex Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024

Gennex Laboratories Limited Announces Resignation of Tiruvarur Muralidharan Gopalakrishnan as Whole Time Director

Gennex Laboratories Limited announced that it has received INR 794.695 million in funding from Premier Fiscal Services Pvt Ltd, Vidya Tradecon Pvt. Ltd., Vivaya Enterprises Private Limited, Jms Mines & Minerals Pvt Ltd

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 17%

Insufficient new directors

Gennex Laboratories Limited announced that it expects to receive INR 966.125 million in funding from Premier Fiscal Services Pvt Ltd

Second quarter 2024 earnings released: EPS: ₹0.17 (vs ₹0.083 in 2Q 2023)

Investor sentiment improves as stock rises 15%

Gennex Laboratories Limited to Report Q2, 2024 Results on Nov 14, 2023

Investor sentiment deteriorates as stock falls 16%

New major risk - Share price stability

Investor sentiment improves as stock rises 19%

Gennex Laboratories Limited, Annual General Meeting, Sep 30, 2023

First quarter 2024 earnings released: EPS: ₹0.16 (vs ₹0.06 in 1Q 2023)

Gennex Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023

Investor sentiment improves as stock rises 25%

New minor risk - Share price stability

Full year 2023 earnings released: EPS: ₹0.32 (vs ₹0.31 in FY 2022)

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: ₹0.067 (vs ₹0.062 in 3Q 2022)

Gennex Laboratories Limited Announces Rajesh Vankadara to Resign as Company Secretary & Compliance Officer Effect from February 26, 2023

Investor sentiment improved over the past week

Second quarter 2023 earnings released: EPS: ₹0.083 (vs ₹0.09 in 2Q 2022)

Now 20% undervalued after recent price drop

Gennex Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Gennex Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022

Gennex Laboratories Limited Receives New 2 Licenses to Manufacture Drugs for Purposes of Examination, Test or Analysis from the Drug Control Administration , Government of Telangana

Full year 2022 earnings released: EPS: ₹0.33 (vs ₹0.32 in FY 2021)

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS ₹0.075 (vs ₹0.029 in 1Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS ₹0.097 (vs ₹0.015 in 3Q 2020)

Gennex Laboratories Limited to Report Q3, 2021 Results on Feb 13, 2021

Investor sentiment improved over the past week

New 90-day high: ₹5.62

New 90-day high: ₹4.94

Gennex Laboratories Limited Appoints A S Nageswar Rao as Additional Director

Market bids up stock over the past week

Market bids up stock over the past week

Gennex Laboratories Limited Announces Resignation of Vinod Choraria as an Independent Director

New 90-day low: ₹3.54